- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00896012
Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal
Phase 4 Study: Comparison of Myfortic and Early Rapamycin Conversion vs. Low-Dose Tacrolimus in Preventing Acute Rejection and Chronic Allograft Fibrosis: A Protocol Biopsy Directed Approach
Current therapy to prevent organ rejection relies on the use of calcineurin inhibitors either cyclosporine or tacrolimus. Although these agents have been very successful in preventing early acute rejection, this success has not translated into improved long-term kidney transplant function. One of the important factors that leads to premature kidney transplant failure is chronic allograft nephropathy (CAN). CAN is characterized by progressive interstitial fibrosis or "scarring", vascular wall thickening, and finally glomerular sclerosis leading to slow progressive loss of kidney function. Calcineurin inhibitors have been shown to play an important role in the pathogens of CAN. Renal transplant recipients in whom calcineurin inhibitors are discontinued enjoy better and longer kidney function. Therefore, immunosuppressive strategies are being designed with the intention of withdrawing calcineurin inhibitors.
The purpose of this trial is to test if tacrolimus can be safely substituted by sirolimus (Rapamycin) and this substitution will yield improved renal function, less CAN and better graft survival rates over the first year.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to determine if tacrolimus can be safely lowered to potentially non-nephrotoxic levels or discontinued completely in favor of Rapamycin 3 months after kidney transplantation. In this study, all patients will be maintained on full-dose (720 mg BID) mycophenolate sodium (Myfortic) to ensure adequate immunosuppression. In addition, we will compare the immunosuppressive regimens of Rapamune/mycophenolate sodium/Prednisone to Low-Dose Prograf/ mycophenolate sodium /Prednisone for their long-term effects on renal function, cardiovascular risk factors, subclinical rejection and chronic allograft fibrosis.
We also plan to examine the clinical benefit of protocol biopsies. The first protocol biopsy would occur at the time of implantation. This would provide an assessment of the state of the donor kidney. The severity of donor disease would provide a baseline to which all subsequent biopsies can be compared. The second protocol biopsy would be performed at the time of tacrolimus withdrawal. Patients found to have subclinical rejection on this biopsy would not undergo tacrolimus withdrawal but may benefit from increased immunosuppression. The protocol biopsy would provide an additional level of safety ensuring that only "low-risk" (histologically) patients undergo tacrolimus withdrawal. A third biopsy would be performed one year after transplantation. Renal allograft tissue would be examined for the presence of progressive fibrosis or persistent subclinical rejection both of which lead to graft failure. The efficacy of tacrolimus withdrawal can be assessed using both clinical and pathologic criteria.
A third aim of this trial is to examine whether changes in immunosuppressive therapy leads to differential expression of immunological markers or serum mediators such as cytokines. Recent studies suggest that, in vitro, thymoglobulin induces the generation of "regulatory" cells. This study will examine the in vivo relevance of this novel observation. In addition, we will measure the circulatory mediators of renal fibrosis to examine if the two treatment arms differ in their effects on such cytokine/growth factors. Blood samples will be collected and the PBMC will be analyzed by FACS for their composition and the presence of cell surface antigens that may reflect a state of immunological regulation or "suppression". Tissue samples will be analyzed by immunohistochemistry for the presence of immunologically relevant cellular subtypes such as CD4/CD25 regulatory T cells. Serum samples will be collected and analyzed for cytokine or growth factor expression.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14203
- Buffalo General Hospital Multi-Organ Transplant Department
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All patients receiving their first renal allograft transplant will be considered eligible for study
- Patients receiving both living and cadaveric donors will be eligible
Exclusion Criteria:
- If less than 18 years of age
- Severe hyperlipidemia
- If pregnant or cannot comply with proper birth control during the study
- Recipients of kidney together with another solid organ or bone marrow transplant
- Patients receiving any investigational medications or participating in a clinical trial
- Patients receiving a second or third renal allograft
- PRA > 30%
- Active infections
- Chronic antiarrhythmic therapy for ventricular arrhythmia
- Malignancy except for basal cell carcinoma
- HIV
- ANC count < 1,000/ mm3, Platelet count < 100,00/mm3
- Fasting triglycerides > 400 mg/dl and cholesterol > 300 mg/dl
- HCV-positive, HBVSAg-positive, HBVCoreAb-positive and HBVSAntibody negative or HCV/HBV co-infected patients
- Breastfeeding women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1. Low-dose tacrolimus arm
Patients in this group will continue to receive tacrolimus at reduced doses.
Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6.
Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months).
All patients will undergo a second protocol biopsy at 12 months.
|
Skin over the kidney will be cleansed and disinfected.
The skin and deeper tissue will be numbed with novocaine like solution.
A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.
Patients in this group will continue to receive tacrolimus at reduced doses.
Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6.
Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months).
|
Experimental: 2. Rapamune conversion arm:
Patients in this group will undergo a gradual conversion from tacrolimus to Rapamune therapy.
Tacrolimus will be withdrawn progressively over a period of 7-10 days.
Dosage adjustments will be made with the aim of reducing the blood levels of tacrolimus by 25% every other day until tacrolimus is discontinued.
Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction.
Thereafter, Rapamune will be given at a dose of 3 mg/day.
The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
|
Skin over the kidney will be cleansed and disinfected.
The skin and deeper tissue will be numbed with novocaine like solution.
A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.
Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction.
Thereafter, Rapamune will be given at a dose of 3 mg/day.
The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Graft Survival at 12 Months
Time Frame: Number of participants biopsied at 12 months post-transplant
|
Graft survival is defined as no rejection or inflammation at 12 months.
|
Number of participants biopsied at 12 months post-transplant
|
Either Equivalent or Improved Estimated Glomerular Filtration Rate (eGFR) at One Year in the Rapamycin Group
Time Frame: 1 year post-transplant
|
Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) formula.
|
1 year post-transplant
|
Improved Histology at 12 Months in the Rapamycin Group
Time Frame: 3 and 12 months
|
Chronic allograft damage index (CADI) scores.
It's a sum score of six histo- pathological lesions commonly seen in biopsies taken from transplanted kidneys that correlate with the function and outcome of the graft.
The maximum CADI score can go up to 18.
In this case the lesions found were Interstitial fibrosis (IF) and Tubular Atrophy (TA) subscales from 0 (min) to 5 (max) .
A score of 0 to 1 means absence of chronic allograft damage, a score of 4 is severe damage. .
|
3 and 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark R Laftavi, MD, FACS, University at Buffalo School of Medicine Deparment of Surgery
- Principal Investigator: Oleh G. Pankewycz, MD, University at Buffalo
Publications and helpful links
General Publications
- Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, Maca J, Hall M; ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004 Feb;4(2):231-6. doi: 10.1046/j.1600-6143.2003.00337.x.
- Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT; Rapamune Maintenance Regimen Study Group. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation. 2003 Jul 27;76(2):364-70. doi: 10.1097/01.TP.0000074360.62032.39.
- Ruiz JC, Campistol JM, Grinyo JM, Mota A, Prats D, Gutierrez JA, Henriques AC, Pinto JR, Garcia J, Morales JM, Gomez JM, Arias M. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation. 2004 Nov 15;78(9):1312-8. doi: 10.1097/01.tp.0000137322.65953.0a.
- Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, Claesson K, Castagneto M, Campistol JM, Hutchison B, Burke JT, Yilmaz S, Hayry P, Neylan JF; Rapamune Maintenance Regimen Trial. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant. 2004 Jun;4(6):953-61. doi: 10.1111/j.1600-6143.2004.00446.x.
- Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, Gloor JM, Cosio FG, Lund WJ, Kremers WK, Nyberg SL, Ishitani MB, Prieto M, Velosa JA. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant. 2006 Mar;6(3):514-22. doi: 10.1111/j.1600-6143.2005.01177.x.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CERL080AUS59
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Bristol-Myers SquibbCompletedKidney Transplantation: Transplantation, Kidney
-
Nantes University HospitalTerminated
-
Hospices Civils de LyonCompletedKidney Transplantation | Pancreas-kidney TransplantationFrance
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Medical University of ViennaUnknownKidney Function After Transplantation | Outcome After Kidney Transplantation
Clinical Trials on Kidney Biopsy
-
Herlev HospitalOdense University Hospital; Zealand University Hospital; Novo Nordisk A/S; Aarhus... and other collaboratorsRecruitingChronic Kidney Diseases | Diabetic Kidney Disease | Diabetic Nephropathies | Diabetes type2 | Albuminuria | Molecular Sequence Variation | Kidney BiopsyDenmark
-
National Institute of Allergy and Infectious Diseases...CompletedKidney TransplantationUnited States, Australia
-
University of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); The...RecruitingGlomerulosclerosis, Focal Segmental | Membranous Nephropathy | Minimal Change Disease (MCD)United States, Canada
-
Weill Medical College of Cornell UniversityQatar National Research FundSuspendedKidney TransplantationUnited States
-
CHU de ReimsUnknownHenoch Schönlein NephritisFrance
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
University of ManitobaCanadian Institutes of Health Research (CIHR); Canadian National Transplant...RecruitingKidney Transplant; Complications | Rejection of Renal TransplantAustralia, Canada
-
Andriy TrailinCompletedKidney Graft DysfunctionUkraine
-
Simeone Andrulli, MDCompletedKidney DiseasesItaly
-
Karolinska InstitutetUniversité Catholique de LouvainRecruitingLupus NephritisSweden